NCT03194763 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Le Roy J, Vernhet Kovacsik H, Zarqane H, Vincenti M, Abassi H, Lavastre K, Mura T, Lacampagne A, Amedro P
Submillisievert Multiphasic Coronary Computed Tomography Angiography for Pediatric Patients With Congenital Heart Diseases. Circ Cardiovasc Imaging. 2019 Feb;12(2):e008348. doi: 10.1161/CIRCIMAGING.118.008348.
Ultra-low dose multiphasic coronary computed tomography angiography for pediatric patients with congenital heart diseases: A prospective cross-sectional study - 14/08/18 Doi : 10
1016/j.acvdsp.2018.06.036 Julien Le Roy, MSc a, b, c, Hélène Vernhet Kovacsik, MD, Ph.D. d, Hamid Zarqane, MD d, Marie Vincenti, MD a, b, Hamouda Abassi, MSc a, Kathleen Lavastre, MSc a, Thibault Mura, MD, Ph.D. e, Alain Lacampagne, Ph.D. b, Pascal Amedro, MD, Ph.D. a, b, ?

Observational Study for Feasibility and Performance of Sub-millisievert Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Anomalies (CAA) in Paediatric Patients

Details for clinical trial NCT03194763

Clinical trial NCT03194763 - References